Aldeyra Therapeutics (ALDX) Research & Development (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Research & Development for 14 consecutive years, with $3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 59.03% year-over-year to $3.5 million; the trailing twelve-month figure through Jun 2026 stood at $15.6 million (down 63.65% YoY), and the FY2025 full-year result was $25.7 million, down 46.78% from the prior year.
• Research & Development climbed to $3.5 million in Q2 2026 per ALDX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Research & Development topped out at $15.0 million in Q2 2024 and bottomed at $2.4 million in Q1 2026.
• Historically, Research & Development has averaged $8.7 million across 5 years, with a median of $8.0 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Research & Development surged 240.37% in 2024, then slumped 70.58% in 2025.
• Over 5 years, Research & Development stood at $9.0 million in 2022, then slumped by 52.04% to $4.3 million in 2023, then soared by 240.37% to $14.6 million in 2024, then plunged by 70.58% to $4.3 million in 2025, then slipped by 19.03% to $3.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $3.5 million, $2.4 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.